Filtered By:
Specialty: Neurology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 354 results found since Jan 2013.

Does OSA hypercoagulability operates through Protein C and S pathways? (P7.313)
CONCLUSION: These results suggest the association of OSA with disturbance of blood coagulation and this finding urge further investigation by conducting a larger population study.Disclosure: Dr. Ayass has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Nowshad has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Ayass, M., Hassan, S., Nowshad, G. Tags: Sleep: Respiratory Disorders and Other Source Type: research

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Advances in ALS and Other Motor Neuron Diseases Data Blitz Presentations Source Type: research

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (S50.005)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Treatment Trials in Neuromuscular Diseases Source Type: research

Incident Cancer in a Cohort of 3,247 Cancer Diagnosis Free Ischemic Stroke Patients
Conclusions: The annual rate of age-adjusted cancer incidence was higher among ischemic stroke patients compared with those in the general population. The odds of mortality were three folds higher among stroke survivors who developed incident cancer.Cerebrovasc Dis 2015;39:262-268
Source: Cerebrovascular Diseases - April 7, 2015 Category: Neurology Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds
Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces ischemic strokes. Nowadays, non-vitamin K antagonist oral anticoagulants (NOACs) have come into widespread use for cardiogenic embolism prevention in place of warfarin. Recently, cerebral microbleeds (CMBs) have been noticed for their potential implication in cerebral small vessel disease. We hypothesized that NOACs do not have an unfavorable influence over cerebral small vessels and investigated whether NOACs increase CMBs in AF patients in a prospective manner.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2015 Category: Neurology Authors: Tsukasa Saito, Yuichiro Kawamura, Nobuyuki Sato, Kohei Kano, Kae Takahashi, Asuka Asanome, Jun Sawada, Takayuki Katayama, Naoyuki Hasebe Source Type: research

Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment
Severity and functional outcome of patients with cardioembolic stroke (CE) occurring during non-vitamin K antagonist oral anticoagulant (NOAC) treatment remain uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - April 2, 2015 Category: Neurology Authors: Hirofumi Tomita, Joji Hagii, Norifumi Metoki, Shin Saito, Hiroshi Shiroto, Hiroyasu Hitomi, Takaatsu Kamada, Satoshi Seino, Koki Takahashi, Satoko Sasaki, Minoru Yasujima, Ken Okumura Source Type: research

Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
This article is protected by copyright. All rights reserved.
Source: Annals of Neurology - April 1, 2015 Category: Neurology Authors: Adrian R. Parry‐Jones, Mario Di Napoli, Joshua N. Goldstein, Floris H.B.M. Schreuder, Sami Tetri, Turgut Tatlisumak, Bernard Yan, Koen M. van Nieuwenhuizen, Nelly Dequatre‐Ponchelle, Matthew Lee‐Archer, Solveig Horstmann, Duncan Wilson, Fulvio Pomer Tags: Research Article Source Type: research

Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta‐analysis
ConclusionsTherapeutic International Normalized Ratio at stroke onset was associated with early and late improved survival and functional recovery suggesting sustained benefit for warfarin anticoagulation for stroke outcome in atrial fibrillation patients. Long‐term outcome data following stroke in patients taking new oral anticoagulants is required.
Source: International Journal of Stroke - March 22, 2015 Category: Neurology Authors: Niamh Hannon, Ethem M. Arsava, Heinrich J. Audebert, Hakan Ay, Morgan Crowe, Danielle Ní Chróinín, Karen Furie, Catherine McGorrian, Noa Molshatzki, Sean Murphy, Imelda Noone, Martin O'Donnell, Johannes Schenkel, Kit M. Tan, David Tanne, Peter J. Kelly Tags: Research Source Type: research

Differential Effect of B-Vitamin Therapy by Antiplatelet Use on Risk of Recurrent Vascular Events After Stroke Brief Reports
Conclusions— High-dose B vitamin therapy may be associated with a higher risk of recurrent stroke among stroke survivors taking antiplatelets, but does not have a significant effect on recurrent stroke risk in those who are not on antiplatelets. Future randomized controlled trials may consider evaluating the effect of homocysteine lowering among stroke survivors with elevated homocysteine who are not on antiplatelet therapy.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Arshi, B., Ovbiagele, B., Markovic, D., Saposnik, G., Towfighi, A. Tags: Secondary prevention, Antiplatelets, Endothelium/vascular type/nitric oxide Brief Reports Source Type: research

Low Vitamin D Linked to More Severe Stroke, Poor OutcomesLow Vitamin D Linked to More Severe Stroke, Poor Outcomes
A new study finds low vitamin D levels in stroke patients predicted larger infarcts and a higher risk for functional dependence at 3 months. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - February 13, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation
Opinion statement Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, ri...
Source: Current Treatment Options in Neurology - February 11, 2015 Category: Neurology Source Type: research

Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research

Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults Clinical Sciences
Conclusions— Higher FGF23 concentrations were associated with higher risk of cardioembolic but not with other stroke subtypes in community-dwelling adults. Additional studies should delineate reasons for these findings.
Source: Stroke - January 26, 2015 Category: Neurology Authors: Panwar, B., Jenny, N. S., Howard, V. J., Wadley, V. G., Muntner, P., Kissela, B. M., Judd, S. E., Gutierrez, O. M. Tags: Acute Cerebral Infarction, Embolic stroke, Epidemiology Clinical Sciences Source Type: research

Reasons Underlying Non-Adherence to and Discontinuation of Anticoagulation in Secondary Stroke Prevention among Patients with Atrial Fibrillation
Conclusion: Nonadherence to OAC in stroke patients results from fear of potential complications or inconvenience and physicians' concerns regarding functional status. OAC should be initiated wherever possible during the in-hospital stay.Eur Neurol 2015;73:184-191
Source: European Neurology - January 24, 2015 Category: Neurology Source Type: research

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
ConclusionsWarfarin use at acute hospital discharge was still common in the initial years after approval of nonvitamin K antagonist oral anticoagulants, although nonvitamin K antagonist oral anticoagulant users increased gradually. The index stroke was milder and ischemia‐risk indices were lower in nonvitamin K antagonist oral anticoagulant users than in warfarin users. Early initiation of nonvitamin K antagonist oral anticoagulants seemed safe.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Kazunori Toyoda, Shoji Arihiro, Kenichi Todo, Hiroshi Yamagami, Kazumi Kimura, Eisuke Furui, Tadashi Terasaki, Yoshiaki Shiokawa, Kenji Kamiyama, Shunya Takizawa, Satoshi Okuda, Yasushi Okada, Tomoaki Kameda, Yoshinari Nagakane, Yasuhiro Hasegawa, Hiroshi Tags: Research Source Type: research